^
Association details:
| Biomarker: | ALK rearrangement + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)
Published date:
08/21/2020
Excerpt:
A total 132 patients with ALK rearrangement advanced NSCLC from 4 centers in Guangdong province, China were evaluated. All patients received crizotinib treatment...we found that 32.6% of patients (43/132) had tumor-suppressor gene mutations (TP53, PTEN, APC, or RB1), the most common of which was TP53 mutation (39/132)...In patients with and without tumor-suppressor gene mutations, median PFS values were 7.9 months (95% CI 5.2–13.1) and 14.2 months (95% CI 11.9–17.6), respectively (HR 2.094; 95% CI 1.270–3.453; P = 0.0031)...
DOI:
10.3389/fonc.2020.01216
